Bacteriostatic Water · Research brief

Tesamorelin Dosage Guide — Protocols & Precision | Real...

Real Peptides Research TeamEditorial

Updated October 24, 202513 min read

49 WORDS

Short answer

Research published in The Lancet HIV found that tesamorelin reduced visceral adipose tissue (VAT) by 15.2% at 26 weeks compared to 0.1% with placebo—a result no lifestyle intervention has consistently replicated in HIV-associated lipodystrophy populations. Yet the gap between study outcomes and real-world application isn't about the compound's efficacy.

Key takeaways

Tesamorelin is dosed at 2mg subcutaneously once daily in clinical research, reconstituted most commonly with 2mL bacteriostatic water to yield 1mg/mL concentration.
Reconstitution accuracy is non-negotiable—a 10% water volume measurement error creates an 11% dose variance that can push subjects outside the therapeutic window established in controlled trials.
The peptide has a plasma half-life of 26–38 minutes, triggering acute pulsatile growth hormone release from pituitary somatotrophs without sustained GH elevation.
Store lyophilized powder at −20°C; reconstituted vials must remain refrigerated at 2–8°C and are stable for 28 days—temperature excursions above 8°C cause irreversible protein denaturation.
Inject on an empty stomach in the morning to align with secondary circadian GH pulses; food intake within 60–90 minutes blunts GH response via insulin-mediated somatostatin upregulation.
Clinical trials demonstrated 15.2% visceral adipose tissue reduction at 26 weeks (The Lancet HIV) and −11.9% mean VAT change from baseline in dose-ranging studies (JCEM).

We've worked with researchers across metabolic health studies for years. The most common point of failure isn't the protocol design—it's the preparation stage, where a miscalculated bacteriostatic water volume or improper peptide handling invalidates months of planning.

What is the correct tesamorelin dosage for research applications?

Tesamorelin is dosed at 2mg administered subcutaneously once daily, typically in the morning on an empty stomach. Clinical trials establishing efficacy for visceral fat reduction used this exact dose consistently across HIV and non-HIV populations. Reconstitution requires precise bacteriostatic water measurement—most commonly 2mL added to a 2mg vial, yielding a 1mg/mL concentration where 1mL = one full daily dose.

This isn't a beginner-friendly peptide. Tesamorelin demands exacting preparation because it's a growth hormone-releasing hormone (GHRH) analog with a short plasma half-life of approximately 26–38 minutes after subcutaneous injection. The compound doesn't accumulate—each dose triggers an acute, pulsatile release of endogenous growth hormone from anterior pituitary somatotrophs, mimicking the body's natural secretion pattern. That brief biological window means dosing consistency and reconstitution accuracy aren't optional—they determine whether the peptide achieves therapeutic levels or degrades before reaching target receptors. This guide covers the exact tesamorelin dosage guide protocols used in published trials, reconstitution math that prevents costly errors, injection timing that maximizes pulsatile GH release, and the storage mistakes that silently destroy peptide integrity.

Standard Tesamorelin Dosage Protocols in Clinical Research

The 2mg daily subcutaneous dose didn't emerge arbitrarily—it was identified through dose-ranging Phase II trials published in the Journal of Clinical Endocrinology & Metabolism, where 1mg, 2mg, and 3mg doses were compared across 12-week intervals. The 2mg dose produced the optimal balance: statistically significant VAT reduction (mean −11.9% from baseline) with manageable adverse event rates (primarily injection site reactions and transient arthralgias in 15–20% of subjects). The 1mg dose showed VAT reduction trends that didn't reach significance; the 3mg dose increased adverse events without proportional efficacy gains.

Tesamorelin's mechanism explains why dose precision matters. The peptide binds to GHRH receptors on pituitary somatotrophs, triggering intracellular cAMP signaling that releases stored growth hormone in discrete pulses lasting 90–120 minutes. This pulsatile pattern differs fundamentally from exogenous GH administration, which creates sustained supraphysiological levels. Pulsatile release preserves negative feedback regulation—growth hormone secretion triggers hepatic IGF-1 production, which inhibits further GH release until levels decline. Overdosing tesamorelin doesn't extend the pulse duration; it amplifies peak GH concentrations without lengthening the biological effect window, increasing adverse event risk (hyperglycemia, fluid retention, joint pain) without therapeutic gain.

Reconstitution accuracy determines final concentration, which directly controls dose delivery. A 2mg lyophilized peptide vial reconstituted with 2mL bacteriostatic water yields 1mg/mL—a 1mL injection delivers the full 2mg dose. Reconstituting the same vial with 1mL water yields 2mg/mL—a 1mL injection now delivers 4mg, double the intended dose. This isn't a 5% margin of error scenario. Peptide concentration scales linearly with water volume, meaning a 10% measurement error (1.8mL instead of 2mL) creates an 11% dose variance, potentially pushing subjects above the therapeutic window established in controlled trials.

Injection timing follows circadian GH secretion patterns. Endogenous growth hormone pulses peak during deep sleep (stages 3–4 NREM) and again in early morning hours. Administering tesamorelin in the morning on an empty stomach aligns with the secondary physiological pulse, avoiding competition with endogenous nocturnal secretion. The fasted state matters—insulin suppresses GH release via somatostatin upregulation, so food intake within 60–90 minutes of injection blunts the pulsatile response. Clinical trial protocols specified morning dosing with a minimum 8-hour overnight fast, and subjects were instructed to delay breakfast 30–45 minutes post-injection.

Real Peptides supplies research-grade Tesamorelin Peptide manufactured through small-batch synthesis with exact amino-acid sequencing, guaranteeing purity and consistency for metabolic research protocols. Our commitment to precision extends across the full peptide collection—every compound is third-party verified for identity and concentration before shipping.

Reconstitution Ratios and Injection Volume Calculation

Reconstitution errors account for the majority of failed peptide protocols—not from ignorance, but from imprecise measurement tools. A standard 1mL insulin syringe measures in 0.01mL increments (hundredths), which works for small volumes but introduces compounding error at larger volumes. Drawing 2.0mL across two separate 1mL syringes risks cumulative measurement variance of ±0.04mL, translating to a 2% dose error. Using a 3mL syringe with 0.1mL graduations (tenths) introduces a potential ±0.05mL error per 2mL draw—a 2.5% variance.

The solution: use a calibrated 3mL Luer-lock syringe with 0.1mL graduations, draw to the 2.0mL line under good lighting, and verify the meniscus sits precisely at the calibration mark. Inject bacteriostatic water slowly down the inside wall of the vial—never directly onto the lyophilized peptide puck, which can denature protein structures through mechanical shear stress. Allow the vial to sit undisturbed for 60–90 seconds; tesamorelin reconstitutes fully without agitation. Gentle swirling (not shaking) ensures homogeneity if any visible powder remains.

Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, extending multi-dose vial stability to 28 days under refrigeration. Sterile water lacks preservatives—once a vial is punctured, bacterial contamination risk rises sharply beyond 24 hours. For a 26-week research protocol requiring 182 daily injections, bacteriostatic water is non-negotiable. Bacteriostatic Water from verified pharmaceutical suppliers ensures the 0.9% benzyl alcohol concentration remains within USP specifications.

Dose calculation follows a simple formula: (desired dose in mg) ÷ (concentration in mg/mL) = injection volume in mL. For a 2mg dose from a 1mg/mL solution: 2 ÷ 1 = 2mL. If reconstituting a 5mg vial with 2mL bacteriostatic water, concentration becomes 2.5mg/mL. To deliver 2mg: 2 ÷ 2.5 = 0.8mL. If reconstituting with 2.5mL instead: 5 ÷ 2.5 = 2mg/mL, and 2 ÷ 2 = 1mL per dose.

Subcutaneous injection sites rotate to prevent lipohypertrophy (localized fat accumulation from repeated trauma). The abdomen 2 inches lateral to the umbilicus, outer thigh mid-quadriceps, and posterior upper arm are standard. Pinch the skin to create a fold, insert the needle at a 45–90° angle depending on subcutaneous fat thickness, and inject slowly over 5–10 seconds. Rapid injection increases injection site pain and can create a depot effect where peptide absorption slows unpredictably.

We've seen researchers struggle with multi-dose vial math when switching between different peptide concentrations mid-protocol. The cardinal rule: recalculate every time the vial changes. Don't assume the previous vial's "1mL = 2mg" ratio carries forward—verify concentration independently for every new reconstitution.

Storage Temperature, Stability Windows, and Degradation Pathways

Tesamorelin is a modified 44-amino acid peptide—structurally larger and more fragile than small-molecule drugs. Lyophilized (freeze-dried) powder remains stable at −20°C for 24–36 months, but once reconstituted, the stability window collapses to 28 days under refrigeration at 2–8°C. Temperature excursions above 8°C initiate irreversible protein denaturation: hydrogen bonds destabilize, tertiary structure unfolds, and receptor binding affinity plummets. This isn't a gradual potency decline—it's a threshold effect. A vial left at room temperature (20–25°C) for 6–8 hours may lose 30–50% biological activity with no visible change in appearance.

Refrigeration doesn't mean "anywhere in the fridge." The door compartment experiences the widest temperature swings—every opening cycle introduces warm air. Store reconstituted peptides on a middle shelf toward the back, where temperature remains most stable. Use a refrigerator thermometer to verify consistent 2–8°C range; many household refrigerators cycle between 1°C and 10°C depending on load and ambient temperature.

Freezing reconstituted peptides is catastrophic. Ice crystal formation physically shears peptide chains and disrupts tertiary structure. A frozen-then-thawed vial may appear normal—clear, no precipitate—but GHRH receptor binding studies show frozen peptides lose 60–90% affinity even after a single freeze-thaw cycle. If a vial accidentally freezes, discard it. The financial loss is immediate; the research integrity loss is worse because you won't know the peptide is inert until results fail to replicate.

Light exposure, particularly UV wavelengths, photooxidizes aromatic amino acids (tryptophan, tyrosine, phenylalanine) in the peptide backbone. Store vials in the original amber glass container or wrap in aluminum foil if transferred to a clear vial. Even indirect sunlight through a window can degrade peptides over days to weeks.

Travel presents the highest storage risk. A peptide vial in checked luggage experiences cargo hold temperatures ranging from −20°C to 30°C depending on flight duration and ground delays. Use an insulated medical travel case with gel ice packs rated for 24–48 hour cold retention. For domestic travel under 12 hours, a quality insulated case maintains 2–8°C; for international flights, consider shipping peptides separately via cold-chain courier to the destination ahead of arrival.

Our research-grade compounds—including options like Sermorelin and Ipamorelin—are manufactured with cold-chain integrity from synthesis to delivery. Every peptide ships in temperature-controlled packaging with freeze indicators that verify no temperature excursions occurred in transit.

Tesamorelin Dosage Guide: Clinical Comparison Across GHRH Analogs

Understanding how tesamorelin compares to other growth hormone secretagogues clarifies why dosing precision varies by compound class and mechanism.

| GHRH Analog | Standard Dose | Administration Frequency | Mechanism of Action | Half-Life | Primary Research Application | Bottom Line | |---|---|---|---|---|---| | Tesamorelin | 2mg subcutaneous | Once daily (morning fasted) | GHRH receptor agonist. Triggers pulsatile GH release from pituitary | 26–38 minutes | Visceral adipose tissue reduction in HIV-associated lipodystrophy; metabolic syndrome research | Most selective for VAT reduction with pulsatile GH release pattern; requires daily dosing due to short half-life | | Sermorelin | 200–300mcg subcutaneous | Once daily (bedtime) | GHRH analog (1–29 fragment). Stimulates endogenous GH secretion | ~10–20 minutes | Age-related GH decline studies; sleep quality research | Shortest half-life of GHRH analogs; physiologically identical to natural GHRH but more cost-sensitive due to frequent dosing | | CJC-1295 (no DAC) | 100–200mcg subcutaneous | 1–3 times daily | GHRH analog with extended half-life via amino acid substitutions | ~30 minutes without DAC modification | Pulsatile GH research; often stacked with GHRP peptides | Preserves pulsatile secretion without DAC; frequently combined with Ipamorelin for synergistic GH release | | CJC-1295 (with DAC) | 2mg subcutaneous | Once or twice weekly | GHRH analog with Drug Affinity Complex. Binds serum albumin for extended release | 6–8 days | Long-duration GH elevation studies | Longest half-life enables infrequent dosing but creates non-pulsatile, sustained GH elevation—less physiological | | Ipamorelin (GHRP) | 200–300mcg subcutaneous | 1–3 times daily | Ghrelin receptor agonist (growth hormone secretagogue). Different pathway from GHRH | ~2 hours | Often stacked with GHRH analogs; appetite and body composition research | Not a GHRH analog—works via ghrelin receptors; synergistic when combined with tesamorelin or CJC-1295 |

Tesamorelin's 2mg daily dose is significantly higher in absolute micrograms than sermorelin or CJC-1295, but potency per microgram varies by receptor binding affinity and plasma stability. The therapeutic effect depends on area-under-the-curve GH release, not peak dose—tesamorelin's structural modifications enhance resistance to enzymatic degradation, allowing a longer effective window despite the short half-life.

What If: Tesamorelin Dosage Scenarios

What If I Reconstituted With the Wrong Water Volume?

Recalculate your concentration immediately using the formula: (total mg in vial) ÷ (actual mL added) = new concentration in mg/mL. If you added 1.5mL instead of 2mL to a 2mg vial, your concentration is 2 ÷ 1.5 = 1.33mg/mL. To deliver a 2mg dose: 2 ÷ 1.33 = 1.5mL per injection. Mark the vial clearly with the corrected concentration and dose volume to avoid repeating the error. If the error resulted in a concentration so high that the required injection volume exceeds 2mL (the practical limit for subcutaneous injection comfort), dilute the solution by adding more bacteriostatic water and recalculating—though this introduces additional contamination risk from repeated vial punctures.

What If the Peptide Vial Was Left Out of the Refrigerator Overnight?

Discard the vial if it remained at room temperature (20–25°C) for more than 4–6 hours. Tesamorelin's protein structure denatures progressively above 8°C, and there's no reliable way to assess potency loss without laboratory assays that measure GHRH receptor binding affinity. Visual inspection is meaningless—denatured peptides remain clear and colorless. Attempting to use a temperature-compromised vial introduces uncontrolled variables into the research protocol, invalidating any data collected. The cost of replacing one vial is negligible compared to the cost of drawing conclusions from degraded peptide data.

What If I Need to Travel With Reconstituted Tesamorelin for a Week?

Use a medical-grade insulated travel case with refreezable gel packs rated for 24–48 hour cold retention, and refresh ice packs every 12–24 hours depending on ambient temperature. TSA allows medically necessary liquids and cooling packs through security when declared; bring a copy of the research protocol or supplier documentation if questioned. For trips longer than 72 hours, consider shipping the peptide via cold-chain courier to your destination address 2–3 days before arrival—services like Cryoport and ThermoSafe specialize in temperature-controlled biological shipments. Alternatively, pause the protocol during travel rather than risk temperature excursions that silently destroy peptide integrity.

What If I Miss a Daily Dose?

Administer the missed dose as soon as you remember if fewer than 12 hours have passed since the scheduled time. If more than 12 hours have passed, skip the missed dose entirely and resume the regular schedule the next morning—do not double-dose to compensate. Tesamorelin's short half-life means missing one dose doesn't create dangerous accumulation if you double up, but it does create a non-physiological GH spike that wasn't present in the clinical trial protocols establishing safety and efficacy. Consistency matters more than perfection; a single missed dose in a 26-week protocol has negligible impact on VAT reduction outcomes.

The Precise Truth About Tesamorelin Dosing

Here's the honest answer: most researchers who report "tesamorelin didn't work" made a preparation error, not a protocol error. The peptide works exactly as the clinical data predicts when reconstituted correctly, stored properly, and administered on schedule. The problem is that peptide research demands pharmaceutical precision in non-pharmaceutical settings—researchers without compounding pharmacy training are expected to perform reconstitution math, sterile technique, and cold-chain management without formal instruction.

The 2mg daily dose is non-negotiable because it's the only dose with Level 1 evidence from randomized, placebo-controlled trials published in peer-reviewed journals. Increasing to 3mg doesn't produce 50% better results—it produces 50% more adverse events with minimal additional VAT reduction. Decreasing to 1mg saves money but sacrifices statistical significance in outcomes. The dose-response curve for tesamorelin is steep and narrow; the therapeutic window sits precisely where the clinical trials placed it.

What guides and protocols often omit: bacteriostatic water quality varies by supplier, and benzyl alcohol concentration outside the 0.9% USP standard creates preservative failure—bacterial contamination doesn't always produce visible cloudiness or odor before it causes injection site infections. Syringe accuracy varies by manufacturer; not all "1mL" syringes deliver exactly 1.00mL at the marked graduation. Using a kitchen scale to verify water volume (1mL = 1g for practical purposes) catches measurement errors before they affect peptide concentration. These details sound obsessive until a $400 research vial fails because of a $0.15 syringe variance.

The peptide research community would benefit from treating reconstitution and administration with the same rigor given to experimental design. Peptides aren't small-molecule drugs that tolerate sloppy handling—they're fragile biologics where a 5°C temperature error or a 0.2mL volume error changes the entire outcome. The precision isn't optional.

The difference between successful tesamorelin protocols and failed ones isn't intellectual—it's mechanical. Use calibrated syringes, verify refrigerator temperatures with a thermometer, calculate concentration independently every time, and store vials away from light and temperature swings. The peptide will perform exactly as published trials predict when the preparation matches the precision those trials maintained.

References

Peer-reviewed sources on Tesamorelin indexed in PubMed, listed for research context. Real Peptides supplies Tesamorelin for laboratory research use only.

Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obesity research & clinical practice, 2026. PMID 41545261. doi:10.1016/j.orcp.2026.01.002
Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs, 2011. PMID 21668043. doi:10.2165/11202240-000000000-00000
Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity. The Journal of infectious diseases, 2025. PMID 39813152. doi:10.1093/infdis/jiaf012
Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS (London, England), 2024. PMID 38905488. doi:10.1097/QAD.0000000000003965
Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial. Journal of clinical and translational science, 2023. PMID 36845310. doi:10.1017/cts.2022.515
Tesamorelin improves fat quality independent of changes in fat quantity. AIDS (London, England), 2021. PMID 33756511. doi:10.1097/QAD.0000000000002897
Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach. Scientific reports, 2021. PMID 34006921. doi:10.1038/s41598-021-89966-y
Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI insight, 2020. PMID 32701508. doi:10.1172/jci.insight.140134

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Tesamorelin is reconstituted by adding 2mL bacteriostatic water to a 2mg lyophilized vial, yielding a 1mg/mL concentration where 1mL delivers the full 2mg daily dose. Inject the water slowly down the inside vial wall—never directly onto the peptide powder, which can cause protein denaturation through mechanical shear stress. Allow 60–90 seconds for the powder to dissolve without agitation, then gently swirl if any visible particles remain. Use a calibrated 3mL Luer-lock syringe with 0.1mL graduations to ensure measurement accuracy within ±2% of target volume.

Clinical trials establishing tesamorelin efficacy used once-daily dosing exclusively; no peer-reviewed data supports twice-daily protocols for visceral fat reduction. The peptide's 26–38 minute half-life triggers a discrete pulsatile growth hormone release lasting 90–120 minutes, after which GH levels return to baseline. Administering a second dose within 12 hours doesn't extend the therapeutic window—it creates overlapping GH pulses that disrupt negative feedback regulation and increase adverse event risk (hyperglycemia, arthralgias) without proportional VAT reduction. The 2mg once-daily morning dose remains the only evidence-based protocol.

At 2mg daily for 30 days, tesamorelin requires 60mg total. Research-grade peptide pricing varies by supplier purity and batch size, typically ranging from $150–$280 per 5mg vial. A monthly supply (twelve 5mg vials) costs approximately $1,800–$3,360 from verified suppliers. Compounded formulations are sometimes available at 40–60% lower cost but lack the batch-level purity verification and third-party testing required for controlled research. Budgeting must also include bacteriostatic water ($8–$15 per 30mL vial), syringes, and cold-chain storage equipment.

Clinical trials reported injection site reactions (erythema, pruritus, pain) in 25–35% of subjects, typically resolving within 7–10 days of continued dosing. Arthralgias (joint pain) occurred in 15–20%, peripheral edema in 10–15%, and hyperglycemia or elevated HbA1c in 5–8% of participants. Muscle pain and carpal tunnel symptoms appeared in fewer than 5% but were the most common reason for discontinuation when they occurred. These rates come from the Phase III trials published in The Lancet HIV and JCEM; real-world rates may vary depending on subject metabolic health at baseline.

Tesamorelin is dosed at 2mg (2000mcg) daily, whereas sermorelin and CJC-1295 (no DAC) are dosed at 200–300mcg daily—an apparent 7–10× difference in micrograms that reflects binding affinity and plasma stability differences, not potency. Tesamorelin's modified structure resists enzymatic degradation better than sermorelin's 1–29 GHRH fragment, allowing therapeutic effect despite the short half-life. CJC-1295 with DAC uses 2mg dosed weekly instead of daily because the Drug Affinity Complex extends half-life to 6–8 days, creating sustained (non-pulsatile) GH elevation. Absolute microgram comparisons are meaningless without accounting for receptor affinity and pharmacokinetics.

Reconstituted tesamorelin remains stable for 28 days when stored at 2–8°C in bacteriostatic water, based on stability data submitted in FDA approval documentation for Egrifta (the branded formulation). Beyond 28 days, bacterial contamination risk rises and peptide degradation accelerates even under continuous refrigeration. Mark every reconstituted vial with the preparation date and discard exactly 28 days later regardless of remaining volume. Extending use beyond this window to 'save money' introduces uncontrolled variables—peptide potency declines unpredictably, and benzyl alcohol preservative efficacy diminishes, raising infection risk from contaminated multi-dose vials.

Researchers frequently combine tesamorelin with ghrelin receptor agonists like ipamorelin (200–300mcg, 1–3 times daily) to achieve synergistic GH release through dual receptor pathways—GHRH receptors (tesamorelin) and ghrelin receptors (ipamorelin). This stacking approach appears in multiple published protocols studying body composition and metabolic outcomes. However, stacking adds complexity: two peptides require separate reconstitution, storage, and administration, doubling the points of potential preparation error. No head-to-head trials compare single-agent tesamorelin to tesamorelin plus ipamorelin specifically for VAT reduction, so stacking protocols remain empirical rather than evidence-based.

Intramuscular injection accelerates absorption, creating a sharper, higher peak GH release that dissipates more quickly than the intended subcutaneous pharmacokinetic profile. This isn't dangerous in a single instance but alters the dose-response curve—peak GH may be 20–40% higher while total exposure (AUC) remains similar, potentially increasing transient adverse events like joint pain or glucose elevation. Subcutaneous injection into pinched skin at a 45–90° angle deposits peptide into adipose tissue for gradual absorption; IM injection at 90° into relaxed muscle bypasses this buffering. If accidental IM injection occurs, monitor for heightened side effects over the next 2–4 hours and return to proper SC technique for subsequent doses.

Clinical trials initiated subjects at the full 2mg dose without titration—there is no published evidence supporting a gradual escalation protocol for tesamorelin as exists for GLP-1 agonists. The adverse event profile (injection site reactions, arthralgias, edema) didn't decrease with slower dose escalation in pilot studies, and the therapeutic mechanism (pulsatile GH release) doesn't benefit from receptor upregulation over time. Starting at 2mg from day one aligns with the trial protocols that established efficacy and safety. Researchers concerned about tolerability in sensitive populations sometimes use 1mg for the first 7 days, but this is empirical practice without controlled data support.

The Lancet HIV trial demonstrated statistically significant VAT reduction at 12 weeks, with peak reduction (15.2% vs 0.1% placebo) occurring at 26 weeks. Most subjects showed measurable VAT decline by week 8–12 when assessed via CT or MRI at the L4–L5 vertebral level, the standard anatomical landmark for visceral adipose quantification. Subcutaneous fat did not decrease proportionally—tesamorelin's effect is selective for visceral depots, likely mediated through GH-stimulated lipolysis preferentially affecting metabolically active intra-abdominal adipocytes. Expecting visible changes before 8–10 weeks is unrealistic; VAT reduction precedes changes in waist circumference or body weight by several weeks.

Bacteriostatic water is required for multi-dose vials used over days to weeks—its 0.9% benzyl alcohol content prevents bacterial growth after repeated needle punctures, extending safe use to 28 days under refrigeration. Sterile water lacks preservatives, so once the vial seal is broken, bacterial contamination risk rises sharply beyond 24 hours even with refrigeration and sterile technique. For a 2mg vial delivering one 2mL dose, sterile water is technically acceptable because the vial is single-use. For any protocol requiring multiple draws from one vial (e.g., a 10mg vial reconstituted for five 2mg doses), bacteriostatic water is non-negotiable.

Clinical trials enrolled both men and women at the identical 2mg daily dose without sex-based adjustments—FDA approval for Egrifta (tesamorelin) applies to both sexes equally. Endogenous GH secretion differs by sex (women have higher baseline pulsatile GH due to estrogen modulation), but tesamorelin's exogenous GHRH receptor stimulation overrides this baseline difference. Adverse event rates and VAT reduction percentages showed no statistically significant sex-based variation in the pivotal trials. Body weight and composition differences between individuals matter more than sex for therapeutic response, but dose remains 2mg daily regardless.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA